Fiche publication
Date publication
octobre 2012
Journal
Haematologica
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CASASNOVAS Olivier
,
Pr DELMER Alain
Tous les auteurs :
Delfau-Larue MH, de Leval L, Joly B, Plonquet A, Challine D, Parrens M, Delmer A, Salles G, Morschhauser F, Delarue R, Brice P, Bouabdallah R, Casasnovas O, Tilly H, Gaulard P, Haioun C
Lien Pubmed
Résumé
In angioimmunoblastic T-cell lymphoma, symptoms linked to B-lymphocyte activation are common, and variable numbers of CD20(+) large B-blasts, often infected by Epstein-Barr virus, are found in tumor tissues. We postulated that the disruption of putative B-T interactions and/or depletion of the Epstein-Barr virus reservoir by an anti-CD20 monoclonal antibody (rituximab) could improve the clinical outcome produced by conventional chemotherapy.
Mots clés
Aged, Antibodies, Monoclonal, Murine-Derived, administration & dosage, Antineoplastic Combined Chemotherapy Protocols, adverse effects, B-Lymphocytes, drug effects, Cyclophosphamide, adverse effects, Doxorubicin, adverse effects, Female, Humans, Immunoblastic Lymphadenopathy, drug therapy, Lymphoma, T-Cell, drug therapy, Male, Middle Aged, Neoplasm Staging, Prednisone, adverse effects, Rituximab, Treatment Outcome, Vincristine, adverse effects
Référence
Haematologica. 2012 Oct;97(10):1594-602
